These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

756 related articles for article (PubMed ID: 10496388)

  • 1. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.
    Miller JW; Schmidt-Erfurth U; Sickenberg M; Pournaras CJ; Laqua H; Barbazetto I; Zografos L; Piguet B; Donati G; Lane AM; Birngruber R; van den Berg H; Strong A; Manjuris U; Gray T; Fsadni M; Bressler NM; Gragoudas ES
    Arch Ophthalmol; 1999 Sep; 117(9):1161-73. PubMed ID: 10496388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
    Schmidt-Erfurth U; Miller JW; Sickenberg M; Laqua H; Barbazetto I; Gragoudas ES; Zografos L; Piguet B; Pournaras CJ; Donati G; Lane AM; Birngruber R; van den Berg H; Strong HA; Manjuris U; Gray T; Fsadni M; Bressler NM
    Arch Ophthalmol; 1999 Sep; 117(9):1177-87. PubMed ID: 10496389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes.
    Sickenberg M; Schmidt-Erfurth U; Miller JW; Pournaras CJ; Zografos L; Piguet B; Donati G; Laqua H; Barbazetto I; Gragoudas ES; Lane AM; Birngruber R; van den Bergh H; Strong HA; Manjuris U; Gray T; Fsadni M; Bressler NM
    Arch Ophthalmol; 2000 Mar; 118(3):327-36. PubMed ID: 10721954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.
    Verteporfin In Photodynamic Therapy Study Group
    Am J Ophthalmol; 2001 May; 131(5):541-60. PubMed ID: 11336929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
    Bressler NM;
    Arch Ophthalmol; 2001 Feb; 119(2):198-207. PubMed ID: 11176980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
    Bressler NM; Arnold J; Benchaboune M; Blumenkranz MS; Fish GE; Gragoudas ES; Lewis H; Schmidt-Erfurth U; Slakter JS; Bressler SB; Manos K; Hao Y; Hayes L; Koester J; Reaves A; Strong HA;
    Arch Ophthalmol; 2002 Nov; 120(11):1443-54. PubMed ID: 12427056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
    Azab M; Boyer DS; Bressler NM; Bressler SB; Cihelkova I; Hao Y; Immonen I; Lim JI; Menchini U; Naor J; Potter MJ; Reaves A; Rosenfeld PJ; Slakter JS; Soucek P; Strong HA; Wenkstern A; Su XY; Yang YC;
    Arch Ophthalmol; 2005 Apr; 123(4):448-57. PubMed ID: 15824216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.
    Blumenkranz MS; Bressler NM; Bressler SB; Donati G; Fish GE; Haynes LA; Lewis H; Miller JW; Monés JM; Potter MJ; Pournaras C; Reaves A; Rosenfeld PJ; Schachat AP; Schmidt-Erfurth U; Sickenburg M; Singerman LJ; Slakter JS; Strong A; Vannier S;
    Arch Ophthalmol; 2002 Oct; 120(10):1307-14. PubMed ID: 12365909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Japanese Age-Related Macular Degeneration Tial (JAT) Study Group
    Am J Ophthalmol; 2003 Dec; 136(6):1049-61. PubMed ID: 14644215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.
    Verteporfin Roundtable Participants
    Retina; 2005; 25(2):119-34. PubMed ID: 15689800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes.
    ; ;
    Retina; 2002 Feb; 22(1):6-18. PubMed ID: 11884872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.
    Verteporfin in Photodynamic Therapy Study Group
    Ophthalmology; 2001 May; 108(5):841-52. PubMed ID: 11320011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical trial of verteporfin photodynamic therapy in Chinese age-related macular degeneration with subfoveal predominant choroidal neovascularization patients].
    Chen YX; Ge J; Yan M; Jin CJ; Zhang MX; Dong FT; Lu F; Zhang CF; Zhao JL
    Zhonghua Yan Ke Za Zhi; 2007 Mar; 43(3):198-205. PubMed ID: 17605900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation secondary to age-related macular degeneration.
    Voelker M; Gelisken F; Ziemssen F; Wachtlin J; Grisanti S
    Graefes Arch Clin Exp Ophthalmol; 2005 Dec; 243(12):1241-6. PubMed ID: 16010552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photodynamic therapy with verteporfin for choroidal neovascularization in patients with diabetic retinopathy.
    Ladd BS; Solomon SD; Bressler NM; Bressler SB
    Am J Ophthalmol; 2001 Nov; 132(5):659-67. PubMed ID: 11704027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Verteporfin therapy in age-related macular degeneration (VAM): an open-label multicenter photodynamic therapy study of 4,435 patients.
    Bessler NM;
    Retina; 2004 Aug; 24(4):512-20. PubMed ID: 15300071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photodynamic therapy with verteporfin for peripapillary choroidal neovascularization.
    Rosenblatt BJ; Shah GK; Blinder K
    Retina; 2005 Jan; 25(1):33-7. PubMed ID: 15655438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of subfoveal choroidal neovascularization secondary to age related macular degeneration with single treatment of verteporfin photodynamic therapy: a safety and short-term outcome.
    Tayanithi P; Pisankosakul P; Laksakapuk P
    J Med Assoc Thai; 2004 Sep; 87 Suppl 2():S78-82. PubMed ID: 16083167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.